A Phase 1b/2, Open-Label, Dose Escalation and Expansion Study Evaluating the Safety and Efficacy of Entospletinib (GS-9973) With Vincristine and Dexamethasone in Adult Subjects With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Trial Profile

A Phase 1b/2, Open-Label, Dose Escalation and Expansion Study Evaluating the Safety and Efficacy of Entospletinib (GS-9973) With Vincristine and Dexamethasone in Adult Subjects With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 31 Oct 2017

At a glance

  • Drugs Entospletinib (Primary) ; Cytarabine; Dexamethasone; Vincristine
  • Indications Acute lymphoblastic leukaemia
  • Focus Adverse reactions
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 26 Oct 2017 Planned number of patients changed from 35 to 50.
    • 23 Feb 2017 Planned primary completion date changed from 1 Sep 2018 to 1 May 2018.
    • 16 Aug 2016 Planned End Date changed from 1 Sep 2018 to 1 Sep 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top